Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: A randomized, phase III study by the Danish Breast Cancer Cooperative Group

Journal of Clinical Oncology

Volumn 29, Issue 36, 2011, Pages 4748-4754

  Nielsen, Dorte L ^a   Bjerre, Karsten D ^b   Jakobsen, Erik H ^c   Cold, Søren ^d   Stenbygaard, Lars ^e   Sørensen, Peter G ^f   Kamby, Claus ^a   Møller, Susanne ^b   Jørgensen, Charlotte L T ^a   Andersson, Michael ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Danish Breast Cancer Cooperative Group Registry   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INFLUENZA; MAJOR CLINICAL STUDY; METASTASIS; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84555218405     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.9507     Document Type: Article

References (36)

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al: The global breast cancer burden: Variations in epidemiology and survival. Clin Breast Cancer 6:391-401, 2005 (Pubitemid 43078894)
2. Wood WC, Muss HB, Solin LJ, et al: Cancer of the breast, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 7). Philadelphia, PA, Lippincott, Williams, and Wilkins, 2004, pp 169-233
3. Giordano SH, Buzdar AU, Kau SC, et al: Improvement in breast cancer survival: Results from M.D. Anderson Cancer Center protocols from 1975-2000. J Clin Oncol 21:54a, 2002 (suppl; abstr 212)
4. Nabholtz JM, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy: 304 Study Group. J Clin Oncol 17:1413-1424, 1999 (Pubitemid 29220847)
5. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999 (Pubitemid 29368232)
6. Sjöström J, Blomqvist C, Mouridsen H, et al: Docetaxel compared with sequential methotrexate and 5-flourouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194-1201, 1999 (Pubitemid 29359178)
7. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002 (Pubitemid 34651510)
8. Carrick S, Parker S, Thornton CE, et al: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2:CD003372, 2009
9. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995
10. Possinger K, Kaufmann M, Coleman R, et al: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10:155-162, 1999 (Pubitemid 29141301)
11. Spielmann M, Llombart-Cussac A, Kalla S, et al: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60:303-307, 2001 (Pubitemid 32623443)
12. Blackstein M, Vogel CL, Ambinder R, et al: Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 62:2-8, 2002 (Pubitemid 34124219)
13. Silvestris N, Cinieri S, La Torre I, et al: Role of gemcitabine in metastatic breast cancer patients: A short review. Breast 17:220-226, 2008 (Pubitemid 351729153)
14. Dent S, Messersmith H, Trudeau M: Gemcitabine in the management of metastatic breast cancer: A systematic review. Breast Cancer Res Treat 108:319-331, 2008 (Pubitemid 351431074)
15. Mavroudis D, Malamos N, Alexopoulos A, et al: Salvage chemotherapy in anthracyclinepretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial - Greek Breast Cancer Cooperative Group. Ann Oncol 10:211-215, 1999 (Pubitemid 29113182)
16. Fountzilas G, Nicolaides C, Bafaloukos D, et al: Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study. Cancer Invest 18:503-509, 2000 (Pubitemid 30485665)
17. Kornek GV, Haider K, Kwasny W, et al: Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8:1051-1056, 2002 (Pubitemid 34517639)
18. Mavroudis D, Malamos N, Polyzos A, et al: Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: A multicenter phase II study. Oncology 67:250-256, 2004 (Pubitemid 39551709)
19. Brandi M, Vici P, Lopez M, et al: Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: Results of a multicenter phase II study. Semin Oncol 31:13-19, 2004 (suppl 5)
20. Pelegrí A, Calvo L, Antón A, et al: Docetaxel/gemcitabine administered every other week as firstline treatment for metastatic breast cancer: Final results of a phase II trial. Clin Breast Cancer 6:433-488, 2005
21. Vici P, Giotta F, DI Lauro L, et al: Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. Anticancer Res 29:1841-1845, 2009
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Seidman D: Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Williston Park) 18:13-16, 2004 (suppl 12)
24. Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950-3957, 2008
25. Chan S, Romieu G, Huober J, et al: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753-1760, 2009
26. Conlin AK, Seidman AD: Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: Current status and future opportunities. Clin Breast Cancer 8:215-223, 2008 (Pubitemid 351962142)
27. Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551, 2005
28. Khoo KS, Zaidi SHM, Srimuninnimit V, et al: Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: A randomised phase II study. Eur J Cancer 42:1797-1806, 2006 (Pubitemid 44149088)
29. Harvey V, Mouridsen H, Semiglazov V, et al: Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970, 2006 [Erratum:J Clin Oncol 24:5790, 2006] (Pubitemid 46631397)
30. Metro G, Fabi A, Russillo M, et al: Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: Towards optimization of association and schedule. Anticancer Res 28:1245-1258, 2008 (Pubitemid 351578863)
31. Fountzilas G, Dafni U, Dimopoulos MA, et al: A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. Breast Cancer Res 115:87-99, 2009
32. Seidman AD, Brufsky A, Ansari RH, et al: Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol 22:1094-1101, 2011
33. Baselga J, Seidman AD, Rosen PP, et al: HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncology (Williston Park) 11:43-48, 1997 (Pubitemid 27225846)
34. Di Leo A, Chan S, Paesmans M, et al: HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 86:197-206, 2004 (Pubitemid 39070962)
35. Azambuja E, Durbecq V, Rosa DD, et al: HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 19:223-232, 2008 (Pubitemid 351201701)
36. Gudena V, Montero AJ, Glück S: Gemcitabine and taxanes in metastatic breast cancer: A systemic review. Ther Clin Risk Manag 4:1157-1164, 2008